BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported recent company progress and financial results for the second quarter of 2023. “We are dedicated to bringing life-changing, once-and-done […]
Other News
Blackford and AI4MedImaging Announce Partnership to enhance AI solutions offering for Cardiac MRI
EDINBURGH, Scotland, Aug. 10, 2023 (GLOBE NEWSWIRE) — Blackford, the pioneering strategic imaging AI platform and solutions provider, and AI4MedImaging, a cardiac MRI solution provider announce a partnership to make the AI4CMR solution available on the Blackford Platform. AI4CMR will enable Blackford customers to automatically segment and quantify cardiac MRI […]
Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update
NEW HOPE, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its second quarter 2023 financial results and provided a business update. “We are excited about this […]
Acorai receives Breakthrough Device Designation for their non-invasive intracardiac pressure monitor
HELSINGBORG, Sweden, Aug. 10, 2023 /PRNewswire/ — Acorai, a start-up medical device manufacturer from Sweden, today announces that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Acorai’s Heart Monitor, a device for the non-invasive estimation of diastolic pulmonary artery pressure (dPAP), systolic pulmonary artery pressure (sPAP), and mean pulmonary artery […]
Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update
MONTREAL and CHARLOTTE, N.C., Aug. 10, 2023 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the second quarter ended June 30, 2023, and provided a clinical and corporate update. “The remainder of 2023 represents a transformative time for the […]
Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update
PONTE VEDRA, Fla., Aug. 10, 2023 /PRNewswire/ — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, today provided a corporate update in connection with the […]
CorVista Health Welcomes Dr. Tim Attebery as New Board Member
WASHINGTON–(BUSINESS WIRE)–CorVista Health, Inc, a leading digital health company dedicated to improving cardiovascular disease diagnosis, is pleased to announce the election of Dr. Tim Attebery to its Board of Directors. “Our shareholders, along with the leadership team of CorVista Health, are thrilled to have Tim join our Board of Directors” […]
Anteris Technologies Commences US Early Feasibility Study
BRISBANE, Australia & MINNEAPOLIS–(BUSINESS WIRE)–Anteris Technologies Ltd, (Anteris or the Company) (ASX: AVR, OTC: ANTTY) reported today that DurAVR™ Transcatheter Heart Valve (THV), a new class of biomimetic valve and the world’s only biomimetic, single-piece transcatheter aortic valve, was used to successfully to treat patients as part of the DurAVR™ […]
HeartBeam Announces Publication of Foundational Study on the Detection of Heart Attacks
SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, today announced the publication of a foundational study demonstrating the ability of its […]
BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results
SUNNYVALE, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the second quarter of 2023 and filed its quarterly report on Form 10-Q for the three and six months ended […]



